Dr. Isa Maria Steiner
Dr. Isa Maria Steiner
Key Areas of Research
- Health economic evaluation
- Wide-area healthcare provision
Academic Training
| 2019–2025 | PhD (Dr. rer. oec.), Chair of Health Care Management, University of Hamburg |
| 2016–2018 | M.Sc. in Economics, University of Münster |
| 2012–2015 | Licence (Bachelor’s degree) in Economic and Social Administration, University of Strasbourg |
Academic career
| Since 2026 | Research Assistant in the Department of Health Economics on the TransVer project, Carl von Ossietzky University of Oldenburg |
| 2024–2026 | Research Assistant in the Hospital Research Unit, AOK Scientific Institute |
| 2019–2024 | Research Assistant at the Chair of Health Care Management, University of Hamburg |
Publications
| Steiner, I. M., Birkner, B., Martinez, M. W. & Stargardt, T. (2026). Physician-led Switching from Reference Biologics to Biosimilars: What is the Effect on Selected Health-Related Outcomes and Costs for IBD Patients in Germany? Value in Health. https://doi.org/10.1016/j.jval.2026.06.006 |
| Bokemeyer, B., Plachta-Danielzik, S., Steiner, I. M., Pohlschneider, D., Urzica, E., Hartmann, P., Zemke, J., Tappe, U., Schreiber, S., Steinkat, N., Langbrandtner, J., Hüppe, A. & Stargardt, T. (2024). Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO-ASSIST study). Alimentary Pharmacology & Therapeutics, 59(9). https://doi.org/10.1111/apt.1792 |
| Böhm, A.-K., Steiner, I. M. & Stargardt, T. (2023). Market diffusion of biosimilars in off-patent biologic drug markets across Europe. Health Policy, 132. https://doi.org/10.1016/j.healthpol.2023.104818 |
| Steiner, I. M., Bokemeyer, B. & Stargardt, T. (2024). Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease. Eur J Health Econ, 25:539–548. https://doi.org/10.1007/s10198-023-01603-9 |